Wegovy Made Me Sick — Here's What the Evidence Says and What to Do Next

What the trial data actually showed about nausea and vomiting

The STEP 1 trial followed 1,961 adults over 68 weeks on semaglutide 2.4 mg. Gastrointestinal side effects were the most frequently recorded adverse events: nausea affected roughly 44% of participants on semaglutide, compared with about 16% on placebo. Vomiting, diarrhoea and constipation each followed a similar pattern, more common on the active medicine, least common once doses stabilised. The NHS semaglutide medicines page lists nausea, vomiting, diarrhoea, constipation and indigestion as very common side effects — meaning they affect more than one in ten people.

The pattern matters: symptoms are most noticeable in the first few days after a dose increase, and most people find them less intense by the second week. That's partly by design. The escalation schedule exists to let your body adjust gradually. The 0.25 mg starting dose isn't intended to produce significant weight loss; it's a settling-in period. If you're in the escalation phase and you've found that semaglutide made you sick, that response is expected, even if it feels anything but manageable in the moment.

What varies considerably between people is severity. Some experience mild queasiness that's more inconvenient than distressing. Others feel genuinely unwell for several days. Both are within the documented range. If your symptoms are landing somewhere in between, our side effects guide for Wegovy covers the full picture.

Practical things that actually help when Wegovy is making you feel so sick

The evidence on managing GLP-1-related nausea points to a few consistent themes. Eating smaller meals more often reduces the load on a stomach that's already emptying more slowly than usual. Wegovy, like other GLP-1 medicines, slows gastric emptying as part of how it works, that's useful for feeling full sooner, but it means a large meal can sit heavily and trigger nausea or reflux. Fatty, rich or very spicy food tends to make this worse; bland, lower-fat options during the early weeks are genuinely worth trying.

Staying hydrated matters more than it might seem. If vomiting or diarrhoea is persistent, you can lose fluids quickly, and dehydration can compound fatigue and dizziness. Small sips of water throughout the day, rather than large amounts at once, tend to be better tolerated. If you're struggling to keep fluids down for more than 24 hours, contact your prescriber or call NHS 111.

One practical note: timing your injection can make a difference for some people. Those who inject on a Monday sometimes find that any first-couple-of-days queasiness falls during the working week rather than over a weekend. Worth considering if you have the flexibility, and worth planning around holidays and commitments if Wegovy left you feeling sick the first time and you lost a day or two. You can read more on managing nausea while on Wegovy in our related guide.

Lying down straight after eating can worsen reflux. Staying upright for at least an hour post-meal is a small adjustment that several patients find helpful. Beyond diet, moving gently rather than resting completely can also ease nausea for some people, a short walk is usually better than staying horizontal.

Symptoms that go beyond normal: when to get medical help

Most Wegovy-related nausea is unpleasant rather than dangerous. But some symptoms require urgent attention. In January 2026, the MHRA issued a Drug Safety Update specifically about GLP-1 medicines and acute pancreatitis, noting it as an infrequent but potentially serious side effect. The key warning sign is severe, persistent stomach pain (particularly pain that spreads to your back) with or without vomiting. This is not ordinary nausea. If it happens, seek emergency medical help rather than waiting it out.

Other symptoms that shouldn't be ignored: signs of dehydration from severe GI illness (very little urination, dizziness, extreme weakness), gallbladder-type pain (sharp pain in the upper right abdomen), or any allergic reaction such as swelling of the face, lips or throat. These are separate from the common adjustment-phase nausea and need medical assessment promptly.

If you're experiencing persistent symptoms that aren't improving after a couple of weeks at your current dose, or feel genuinely unable to manage, speak to whoever prescribed your treatment. Prescribers can consider slowing down the escalation schedule, which is sometimes the right clinical choice. Stopping abruptly without guidance isn't advisable. You can also report unexpected side effects directly to the MHRA at yellowcard.mhra.gov.uk, the Yellow Card scheme exists precisely so that real-world safety signals reach the regulator.

Whether to continue, pause or review with your prescriber

The question most people end up with after several rough days is whether it's worth continuing. That depends on the severity of your symptoms, where you are in the dose schedule, and your wider clinical picture, none of which a general article can decide for you. What the evidence does show is that dropout rates due to GI side effects were meaningful in the STEP 1 trial, so you wouldn't be unusual for finding it genuinely difficult. At the same time, most people who stay with the treatment through the escalation phase find the symptoms reduce substantially.

If you're on Wegovy through an unrelated provider and you're struggling, our Wegovy overview explains what supervised private treatment looks like and what ongoing prescriber access should include. If you're considering starting and want to understand the full side effect profile before you do, take a look at our weight-loss treatment overview for context on how different options compare. For people exploring the cost side of things, our guide on Wegovy pricing in the UK is worth reading alongside this.

At nume, a real clinician reviews your case before every repeat supply, not just at sign-up. If your experience with nausea has changed, our prescribers want to know. Speak to our prescribers, it costs nothing to start that conversation.